



Curriculum vitae Europass

Informatii personale

Prenume /Nume **Anca Streinu-Cercel**

Experiența profesională

Perioada	2015- in prezent
Functia sau postul ocupat	Medic Primar Boli Infectioase
Activități si responsabilități principale	Conform fisei postului: activitatea de medic in specialitatea boli infectioase in regim de spital si ambulator, activitate de cercetare medicală in domeniul bolilor infectioase
Numele si adresa angajatorului	Institutul National de Boli Infectioase „Prof.Dr. Matei Bals”, Bucuresti
Tipul activității sau sectorul de activitate	Activități medicale in domeniul bolilor infectioase
Perioada	2011- 2015
Functia sau postul ocupat	Medic Specialist Boli Infectioase
Activități si responsabilități principale	Conform fisei postului: activitatea de medic in specialitatea boli infectioase in regim de spital si ambulator, activitate de cercetare medicală in domeniul bolilor infectioase
Numele si adresa angajatorului	Institutul National de Boli Infectioase „Prof.Dr. Matei Bals”, Bucuresti
Tipul activității sau sectorul de activitate	Activități medicale in domeniul bolilor infectioase
Perioada	2006-2011
Functia sau postul ocupat	Medic rezident specialitatea Boli Infectioase
Activități si responsabilități principale	Conform fisei postului: activitatea de medic rezident in specialitatea boli infectioase
Numele si adresa angajatorului	Institutul National de Boli Infectioase „Prof.Dr. Matei Bals”, Bucuresti
Tipul activității sau sectorul de activitate	Activități medicale in domeniul bolilor infectioase
Perioada	2018 - prezent
Functia sau postul ocupat	Medic rezident a 2 specialitate Alergologie si Imunologie Clinica
Perioada	2016 - în prezent
Functia sau postul ocupat	Conferentiar Boli Infectioase – UMF Carol Davila
Activități si responsabilități principale	Conform fisei postului (activitate de predare boli infectioase in cadrul stagiilor clinice, îndrumare lucrarilor de diploma, lucrari de cercetare etc)
Numele si adresa angajatorului	Universitatea de Medicină si Farmacie „Carol Davila”, Bucuresti
Tipul activității sau sectorul de activitate	Medicină, învățământ

Perioada	2011- 2016
Functia sau postul ocupat	Sef de lucrari Catedra de Boli Infectioase – UMF Carol Davila
Activități si responsabilități principale	Conform fisei postului (activitate de predare boli infectioase in cadrul stagiilor clinice, îndrumare lucrarilor de diploma, lucrari de cercetare etc)
Numele si adresa angajatorului	Universitatea de Medicină si Farmacie „Carol Davila” , Bucuresti
Tipul activității sau sectorul de activitate	Medicină, învățământ
Perioada	2009- 2011
Functia sau postul ocupat	Asistent Universitar Catedra de Boli Infectioase – UMF Carol Davila
Activități si responsabilități principale	Conform fisei postului (activitate de predare boli infectioase in cadrul stagiilor clinice, îndrumare lucrarilor de diploma, lucrari de cercetare etc)
Numele si adresa angajatorului	Universitatea de Medicină si Farmacie „Carol Davila” , Bucuresti
Tipul activității sau sectorul de activitate	Medicină, învățământ
Perioada	2006-2009
Functia sau postul ocupat	Preparator Catedra de Boli Infectioase - UMF Carol Davila
Activități si responsabilități principale	Conform fisei postului (activitate de predare boli infectioase in cadrul stagiilor clinice, îndrumare lucrarilor de diploma, lucrari de cercetare etc)
Numele si adresa angajatorului	Universitatea de Medicină si Farmacie „Carol Davila” , Bucuresti
Tipul activității sau sectorul de activitate	Medicină, învățământ
Perioada	2011 – prezent
Functia sau postul ocupat	Membru al board-ului editorial
Activități si responsabilități principale	Managementul stiintific al jurnalului GERMS
Numele si adresa angajatorului	GERMS
Tipul activității sau sectorul de activitate	Publicatie medicală indexată în baze de date internationale (Scopus, PubMed Central, etc.)
Perioada	2011-2012
Functia sau postul ocupat	Redactor sef The Lancet Infectious Diseases – editia in limba română
Activități si responsabilități principale	Coordonarea consiliului stiintific si editorial al revistei
Numele si adresa angajatorului	The Lancet Infectious Diseases
Tipul activității sau sectorul de activitate	Publicatie medicală cotate ISI si indexată in baze de date medicale internationale
Educatie și formare	
Perioada	2022 (Ordin OME nr 6355 din 5.12 /2022)
Calificarea / diploma obtinută	Atestat de abilitare in domeniul studii universitare de doctorat Medicină
Numele si tipul institutiei de învățământ / furnizorului de formare	Universitatea de Medicina si Farmacie Carol Davila București

Perioada	2005-2010
Calificarea / diploma obtinută	Doctor in Stiinte Medicale (PhD)
Disciplinele principale studiate / competente profesionale dobândite	Medicină, Boli Infecțioase – Teza de doctorat: „Managementul terapeutic al hepatitelor virale acute VHB”
Numele si tipul institutiei de învățământ / furnizorului de formare	Universitatea de Medicina si Farmacie Carol Davila- Catedra de Boli Infectioase
Perioada	iunie 2014 – noiembrie 2015
Calificarea / diploma obtinută	Post Doctorand. Proiect POSDRU/159/1.5/S/137390
Disciplinele principale studiate / competente profesionale dobândite	„Cercetarea doctorală si postdoctorală prioritate a învățământului superior românesc (Doc-Postdoc)”. Domeniul major de interventie: 1.5 “Programe doctorale si post-doctorale în sprijinul cercetării”. Axa prioritară: 1. “Educatia si formarea profesională în sprijinul cresterii economice si dezvoltării societății bazate pe cunoastere”. Beneficiar: Universitatea de Medicina si Farmacie Carol Davila din Bucuresti. Fondul Social European. Programul Operational Sectorial pentru Dezvoltarea Resurselor Umane 2007 – 2013- având ca temă de cercetare: <i>Evaluarea osteo-renală a pacientilor infectati HIV-cohorta din Romania</i>
Numele si tipul institutiei de învățământ / furnizorului de formare	Universitatea de Medicina si Farmacie Carol Davila- Catedra de Boli Infectioase
Perioada	2019
Calificarea / diploma obtinută	Medicina de calatorie competenta/ atestat
Disciplinele principale studiate / competente profesionale dobândite	Ministerul Sanatatii, Centrul National Cursuri postuniversitare
Perioada	2017
Calificarea / diploma obtinută	Management sanitar competenta/ atestat
Disciplinele principale studiate / competente profesionale dobândite	Ministerul Sanatatii, Centrul National Cursuri postuniversitare
Perioada	1999-2005
Calificarea / diploma obtinută	Medic (MD)
Disciplinele principale studiate / competente profesionale dobândite	Domeniul medical
Numele si tipul institutiei de învățământ / furnizorului de formare	<i>Universitatea Titu Maiorescu Facultatea de Medicină Generală, Bucuresti, România</i> www.utm.ro
Perioada	1995-1999
Calificarea / diploma obtinută	Diploma de bacalaureat- profilul informatic
Disciplinele principale studiate / competente profesionale dobândite	Profil informatic
Numele si tipul institutiei de învățământ / furnizorului de formare	<i>Colegiul National “Spiru Haret” –, Bucuresti, Romania</i> http://cnshb.ro

Perioada	Aprilie- iunie 2022
Calificarea / diploma obținută	HMX Pro Immunology—Immunology - Novel Therapies for Chronic Inflammation
Numele si tipul institutiei de învățământ	Harvard Medical School - Office of Online Learning, External Education
Perioada	Aprilie- iunie 2022
Calificarea / diploma obținută	HMX Pro Immunology—Vaccines and Viral Immunology
Numele si tipul institutiei de învățământ	Harvard Medical School - Office of Online Learning, External Education
Perioada	Iulie- August 2020
Calificarea / diploma obținută	COVID-19 Training for Healthcare Workers
Numele si tipul institutiei de învățământ	Stanford University on line course
Perioada	Iulie-august 2021
Calificarea / diploma obținută	Leading Digital Transformation in Health Care
Numele si tipul institutiei de învățământ	Harvard Medical School-Executive Education
Perioada	14-16 mai 2019
Calificarea / diploma obținută	Cursul Postuniversitar de Infecții Asociate Asistenței Medicale și Igienă a Mainilor (cod 190)
Numele si tipul institutiei de învățământ	Universitatea de Medicină și Farmacie Carol Davila- Disciplina de Epidemiologie
Perioada	2009-2010
Calificarea / diploma obținută	Diplôme Universitaire –DU
Disciplinele principale studiate / competente profesionale dobândite	Domeniul Medical- Imunologie-Hepatologie
Numele si tipul institutiei de învățământ / furnizorului de formare	<i>Université Pierre et Marie CURIE - Sciences et Médecine - UPMC - Paris</i> www.upmc.fr
Perioada	2008
Calificarea / diploma obținută	Diploma de formator
Numele si tipul institutiei de învățământ / furnizorului de formare	Ministerul Educației, Cercetării, Tineretului și Sportului
Perioada	13 mai – 24 iunie 2014
Calificarea / diploma obținută	Bacteria and Chronic Infections
Disciplinele principale studiate / competente profesionale dobândite	Curs online. Proprietățile biofilmului. Infecțiile cronice. Bacteriile și biofilmul – trăsături comensale. Bacteriile și biofilmul – infecții cronice. Diagnosticarea și tratamentul infecțiilor cronice. Perspective evolutive privind biofilmul.
Numele si tipul institutiei de învățământ / furnizorului de formare	University of Copenhagen
Perioada	9 martie – 19 aprilie 2014
Calificarea / diploma obținută	Design and Interpretation of Clinical Trials

Disciplinele principale studiate / competente profesionale dobândite	Curs online. Tipuri de design, randomizare, obiective si analiză, considerente etice, raportarea rezultatelor, ghidurile Consolidated Standards of Reporting Trials (CONSORT), studii randomizate controlate.
Numele si tipul institutiei de învățământ / furnizorului de formare	Johns Hopkins University
Perioada	11 iunie 2014
Calificarea / diploma obtinută	Curs de competență în utilizarea testelor neinvazive în diagnosticul, stadializarea si tratamentul patologiei hepatice – Bucuresti
Disciplinele principale studiate / competente profesionale dobândite	FibroTest, FibroMax, GenoFibroMax, ElastoFibroTest, FibroSure, FibroMeter, Transient elastography FibroScan, Aixplorer, Shear-wave elastography, CAP (controlled attenuation parameter)
Numele si tipul institutiei de învățământ / furnizorului de formare	Institutul National de Boli Infectioase „Prof. Dr. Matei Bals”, Academia Europeană HIV/SIDA si de Boli Infectioase
Perioada	23 martie - 8 decembrie 2013
Calificarea / diploma obtinută	Postgraduate Course in Clinical Trials Management – Bucuresti
Disciplinele principale studiate / competente profesionale dobândite	Rolul cercetării clinice în dezvoltarea de noi molecule. Statistica în cercetarea clinică. Proiectarea cercetării clinice. Procesul de dezvoltare a unui medicament. Principiile derulării cercetării clinice. Cercetarea clinică în România. Testarea clinică a produselor medicale. Procesarea datelor în studiile clinice. Managementul echipei de proiect. Farmacovigilentă. Cercetare clinică în populatia pediatrică; boli orfane. Management de proiect. Provideri externi în studiile clinice. Planificarea si managementul bugetului în studiile clinice. Managementul riscului. Recrutarea si păstrarea subiecților (workshop). Etica cercetării clinice. Aspecte legale privind cercetarea clinică. Sisteme de asigurare a calității în cercetarea clinică. Management de proiect în studiile clinice. Coaching. Bioechivalentă si studii de fază I.
Numele si tipul institutiei de învățământ / furnizorului de formare	GFKM (Gdansk Foundation for Management Development), GlobalCare Clinical Trials, Universitatea de Medicină si Farmacie Carol Davila din Bucuresti, Institutul National de Boli Infectioase “Prof. Dr. Matei Bals”
Perioada	22 noiembrie - 18 decembrie 2013
Calificarea / diploma obtinută	Antimicrobial stewardship: Optimization of Antibiotic Practices
Disciplinele principale studiate / competente profesionale dobândite	Curs online: <u>Abordarea clinică a științei utilizării antimicrobienulelor</u> : Principii de farmacocinetică si farmacodinamică privind antibioticele; Rezistenta la antibiotice; Rezistenta mycobacteriilor, virusurilor si fungilor; Alergii la antibiotice, etc. <u>Aspecte practice legate de programele de supraveghere a utilizării antimicrobienulelor</u> . <u>Aplicatii în circumstante particulare</u> : Interventii; Instrumente de cuantificare; Profilaxia transmiterii infectiilor, etc.
Numele si tipul institutiei de învățământ / furnizorului de formare	Division of Infectious Diseases, Department of Medicine, Stanford University School of Medicine
Perioada	23 septembrie - 22 noiembrie 2013
Calificarea / diploma obtinută	Writing in the Sciences
Disciplinele principale studiate / competente profesionale dobândite	Curs online. Diateza activă. Verbe. Punctuatie. Paralelism. Structură. Elaborarea unui manuscris. Alternative la cercetare. Manuscrisul original. Plagiarism. Autori. Conflicte de interese. Cercetare reproductibilă. Peer-review. Comunicarea datelor stiintifice.
	Stanford University

Numele si tipul institutiei de învățământ furnizorului de formare	
Perioada	martie 2013
Calificarea / diploma obtinută	GCP Training
Disciplinele principale studiate / competente profesionale dobândite	Declaratia de la Helsinki; ICH-GCP: aspecte generale; ICH-GCP: responsabilitățile investigatorului – capitolul 4; Inspection readiness; Publicatii recente
	Arensia Germania
Perioada	aprilie 2014, martie 2016, mai 2017, mai 2019, august 2020, sept 2021. nov 2022
Calificarea / diploma obtinută	GCP Training refresher
Disciplinele principale studiate / competente profesionale dobândite	Declaratia de la Helsinki; ICH-GCP: aspecte generale; ICH-GCP: responsabilitățile investigatorului – capitolul 4; Inspection readiness; Publicatii recente
	Arensia Germania
Perioada	11 iunie - 18 august 2013
Calificarea / diploma obtinută	HRP258 Statistics in Medicine
Disciplinele principale studiate / competente profesionale dobândite	Curs online. Statistică descriptivă. Tipuri de studii; riscuri si asocieri. Probabilități, Legea lui Bayes. Distributiile probabilităților. Inferenta statistică. Valori p (erori, putere statistică, capcane). Teste statistice. Regresie. Regresie II: regresia logistică, regresia Cox.
Numele si tipul institutiei de învățământ / furnizorului de formare	Stanford University
Perioada	13 decembrie 2012, decembrie 2014, decembrie 2016, decembrie 2018, dec 2019, dec 2021
Calificarea / diploma obtinută	“Transporting Dangerous Goods Certificate” certificare IATA
Disciplinele principale studiate / competente profesionale dobândite	Curs online: Class/Div 6.2 & 9: Clasificare si identificare; Ambalarea; Etichetare si marcare; Documentatia necesară; Proceduri de urgență,
Numele si tipul institutiei de învățământ / furnizorului de formare	Mayo Medical Laboratories
Perioada	16-18 martie 2011
Calificarea / diploma obtinută	Effective Clinical Trial Project Management, Bucuresti
Disciplinele principale studiate / competente profesionale dobândite	Curs de management de proiect eficient în domeniul studiilor clinice. 30 de puncte CPD
Numele si tipul institutiei de învățământ / furnizorului de formare	The Institute of Clinical Research
Perioada	4 iunie 2010
Calificarea / diploma obtinută	„Training avansat asupra normelor Good Clinical Practice în cercetarea clinică”, Certificat de absolvire nr. 9/04.06.2010, 6 credite EMC, Bucuresti
Disciplinele principale studiate / competente profesionale dobândite	ICH GCP (roluri si responsabilități, documente esentiale); Directivele EU Clinical Trial si GCP (cuprinsul directivelor, continutul „Clinical Trial Directive”, autorizatii, amendamente si notificări, continutul „CGP Directive”, arhivarea, IMPs), protectia datelor (principii generale, impactul asupra cercetării clinice); consimțământul informat (aspecte-cheie, subiecte

vulnerabile); raportarea problematicii sigurantei (definitii, raportare, cerinte); inspectiile autorităților reglatorii (abordarea generală, identificarea eventualelor probleme, răspunsul la eventualele probleme identificate); fraudă (definitie, impact, prevenție și detectie).

Numele și tipul instituției de învățământ / furnizorului de formare

The Institute of Clinical Research, UK. Colegiul Medicilor din România (CMR), București.

Aptitudini și competențe personale

Organizare de module de formare în parteneriat cu ESCMID/ESGVH- Hepatitis B can we cure? nov 2022
EUCIC BIOFILM module ian 2019
Virology Education CEE Bucharest meeting 2017, 2023
Evaluator research projects presented with reference to the Call for Grant 2013, Grant 2015 Italian Ministry of Health- Directorate-General for Research and Innovation in Healthcare
7 th EACS Advanced HIV Course, Montpellier, Franța-sept 2009 European AIDS
Exchange program noiembrie- decembrie 2009 Pitie-Salpetrie Assistance Publique Paris,- clinica de hepatologie Prof. Poynard și clinica de boli infecțioase Prof. Bricrere/Katlama
Diplomă de formator- Ministerul Educației și Învățământului 2008
Diploma de mediator medical - Ministerul Educației și Învățământului 2008

- "Fourth International Summer School on Reasoning under Partial Knowledge" "Universitatea Internațională de vară Reason Park", Foligno (Perugia), Italia Medicina-logica fuzzy 2004
- Opioid treatment –INBI Prof. Dr. Matei Bals, National Society of Oncology- June 2008
- Management Risk- Sanitary Mediator Curs- INBI Prof. Dr. Matei Bals- June-July 2008
- "BLS and ALS Course", 15 April 2006, Municipal Emergency Hospital, Bucharest
- "Speaker training seminar"- BMS Course- Glasgow -November 2008
- "Renal and hepatic biopsy"- "Fundeni Institute", Bucharest, 27 February – 3 March 2006
- "Basics Life support and Advance life support Course", 22 May- 27 May 2005, SMURD unit Sinaia,
- "Effective Presentation Skills", Bucharest, 16-18 June 2004
- "Negotiation Skills – win-win", "Third Millennium Leadership Program me" OPEN University – CODECS and British Council, March-June 2004, Bucharest
- "Education for Prevention of Human being Traffic", June 2002, Bucharest
- Membru în comitetul de organizare al congresului: Zilelor Științifice ale Institutului National de Boli Infecțioase „Prof. Dr. Matei Bals din 2010, *editia anuala - in nov 2019 a ajuns la editia a XX a*
- 23-25 octombrie 2013 – București, România. Membru în comitetul de organizare al congresului: a IX-a Editie a Zilelor Științifice ale Institutului National de Boli Infecțioase „Prof. Dr. Matei Bals"
- 17-19 octombrie 2012 – București, România. Membru în comitetul de organizare al congresului: a VIII-a Editie a Zilelor Științifice ale Institutului National de Boli Infecțioase „Prof. Dr. Matei Bals": Bolile Infecțioase – Sens unic
- 13-16 octombrie 2010 – București, România. Membru în comitetul de organizare al congresului: a VI-a Editie a Zilelor Științifice ale Institutului National de Boli Infecțioase „Prof. Dr. Matei Bals"

Limbi străine cunoscute
 Autoevaluare
 Nivel european (*)

	Întelegere		Vorbire		Scriere
	Ascultare	Citire	Participare la conversație	Discurs oral	Exprimare scrisă
Engleză	C2	C2	C2	C2	C2
Franceză	C2	C2	C2	C2	C1

(*) [Nivelul Cadrelui European Comun de Referință Pentru Limbi Străine](#)

Competente si abilități sociale	<p>Abilități de comunicare – dezvoltate in urma experientei practice de cadru universitar al facultatii de medicina, al interactiuni cu pacienti in calitate de medic rezident si specialist, in activitatea de spital, ambulator si studii clinice internationale</p> <p>Abilități de prezentare- dobândite in urma participarii la cursurile teoretice de tehnici de prezentare si a experientei practice dabantite prin sustinerea de lucrări stiintifice in cadrul sesiunilor de comunicari, simpozioane si congreselor nationale si internationale</p> <p>Capacitatea de a lucra in echipă-dobândită in urma participarii in diferite proiecte interdisciplinare, studii clinice internationale, granturi de cercetare,</p> <p>Capacitatea de a lucra intr-un mediu multicultural, prin participarea la evenimente stiintifice internationale: congrese, simpozioane, sesiuni stiintifice si prin stagiile profesionale efectuate in strainătate</p>
Competente si aptitudini organizatorice	<p>Abilitati de conducere dezvoltate prin coordonarea activitatii departamentului de studii clinice din cadrul INBI Matei Bals, coordonarea in calitate de redactor sef a editiei in limba romana a revistei The Lancet Infectious Diseases, coordonarea lucrarilor de diplomă/licență ale studentilor la medicina</p> <p>Study coordinator in cadrul unor proiecte medicale internationale</p> <p>Abilități organizatorice dobândite in urma organizarii de simpozioane stiintifice, sesiunilor stiintifice, congrese nationale si cu participare internatională</p> <p>Management de proiect, abilitate dezvoltata prin participarea la cursuri teoretice de Management al proiectelor si al studiilor clinice, aplicată practic prin conducerea proiectelor medicale</p>
Competente si aptitudini tehnice	<p>Punctia biopsie hepatică</p> <p>Specialist Fibroscan- elastometrie hepatică (LSM-liver stiffness mesurment)</p>
Competente si aptitudini de utilizare a calculatorului	<p>Abilitati de utilizare Microsoft Office (Word™, Excel™ si PowerPoint™), dobandită practic prin utilizarea Power Point-ului in realizarea si sustinerea de prezentari medicale, cursuri si seminarii pentru studenti, a Word-ului pentru redactarea de lucrari de licenta, articole de specialitate, a Excel-ului pentru prelucrarea datelor medicale.</p> <p>Utilizarea soft-urilor medicale de statistică in cadrul proiectelor stiintifice de cercetare</p>
Permis de conducere	Categororia B
Informatii suplimentare	<p>Cursuri de scurta durata:</p> <p>Speaker in peste 300 de evenimente nationale si internationale, cateva dintre acestea fiind listate mai jos:</p> <ul style="list-style-type: none"> • Speaker in cadrul Virology Education https://www.virology-education.com, la evenimente internationale, din anul 2012, 2013, 2014, 2015-2020, 2021, 2022 • Speaker International Forum HIV and Hepatitis oct 2020, 2022 • Speaker International Forum HIV and Hepatitis oct 2018, 2019 • Speaker in cadrul proiectului POCU in cadrul programelor de formare personal medical pe parcursul anilor 2018-2021 • Speaker in cadrul Scolii Internationale de iarnă, Viral Hepatic Infectious- medical and bioethical approach, Attersee, Austria 11-18 February 2011, coordonată de Colegiul Medicilor din Romania si European HIV/AIDS and Infectious Diseases Academy. • Speaker in cadrul Cursului de formare: Chronic Viral Hepatitis, European HIV/AIDS and Infectious Diseases, Bucharest, June 2010 • Certificate of Advanced Training in Good Clinical Practice for Clinical Research Professionals, Bucharest, June 2010 • 7th EACS Advanced HIV Course- September 2009- Montpellier France organized by EACS (European AIDS Clinical Society) -Montpellier Faculty of Medicine • “Fourth International Summer School on Reasoning under Partial Knowledge” “International Summer University Reason Park”, September 2004, Foligno (Perugia), Italia • Research/Exchange program at Assistance Publique Pitie Salpetrie, Paris- hepatology department and infectious disease department November 2009- December 2009

**Membru în societăți
nationale și internaționale**

- International Summer School – Traveler medicine- Ovidius Medical University Constanta – July 2010
- International Summer School – Traveler medicine- Ovidius Medical University Constanta - September 2008
- membru al ESGVH (ESCMID study group on Viral Hepatitis)
- membru al ENYHE (European Network of Young HIV Experts)
- Din 2013 – membru fondator al SIMCR și co-presedinte (Societatea Internațională de Medicină și Chirurgie Regenerativă) 2013-2022
- Din 2013 – membru fondator al SBIHS (Societatea de Boli Infecțioase și HIV/SIDA), secretar general din 2017
- membru al ESCMID (European Society of Clinical Microbiology and Infectious Diseases)
- membru al IAS (International AIDS Society)
- membru EACS (European AIDS Clinical Society), membru WAVE
- Neatid – The European treatment network for HIV, hepatitis and global infectious diseases
- ISARIC – International Severe Acute Respiratory and Emerging Infection Consortium
- MERMAIDS 2 ARI – European Study of MAJOR Infectious Disease Syndromes Related to COVID-19
- REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia)
- DRIVE – Development of Robust and Innovative Vaccine Effectiveness (Increasing understanding of influenza vaccine effectiveness in Europe)
- GIHSN – Global Influenza Hospital Surveillance Network
- COMBACTE-NET – Combatting bacterial resistance in Europe – Networks

**Activitate editorială –
jurnale stiintifice medicale**

- Din 2015 – **co- editor sef al jurnalului JCCP** Journal of Contemporary Clinical Practice ISSN 2457-7200, publicatie medicală indexată în baze de date internationale
- Din 2011 – membru al board-ului editorial si management stiintific al jurnalului GERMS, publicatie medicală indexată în baze de date internationale (Scopus, PubMed Central, etc.)
- din October 2015-2022 – editor al “Proceedings of the 11th Edition of the Scientific Days of the National Institute for Infectious Diseases “Prof Dr Matei Bals”” publicat în volum cu ISSN:2457-8225, ISSN-L 2457-8525
- October 2014 – editor al “Proceedings of the 10th Edition of the Scientific Days of the National Institute for Infectious Diseases “Prof Dr Matei Bals”” publicat în BMC Infectious Diseases Volum, Supliment
- October 2013 – editor al “Proceedings of the 9th Edition of the Scientific Days of the National Institute for Infectious Diseases “Prof Dr Matei Bals”” publicat în BMC Infectious Diseases Volum 13, Supliment 1
- 2009-2014 – Redactor al jurnalului Therapeutics, Pharmacology and Clinical Toxicology, publicatie medicală cotate CNCSIS B+, indexată în baze de date internationale
- 2011 – Membru al board-ului editorial al jurnalului Clinical Infectious Diseases – editia în limba română, publicatie medicală cotate ISI, indexată în baze de date internationale
- 2011 – redactor sef pentru The Lancet Infectious Diseases – editia în limba română, publicatie medicală cotate ISI, indexată în baze de date internationale

Participări la sesiuni stiintifice:

- HIV Outcomes invited speaker European Parliament 1 december 2022 meeting
- Virology education invited speaker 2016-2022
- 3rd CEE meeting Viral Hepatitis and Co infection with HIV, HIV/Hepatitis co infection situation in Romania, Lublijana, oct 2017
- CEE 2021 14-16 oct 2021, HIV and COVID-19 Coinfection, virtual meeting
- ESCMID/ESGVH Epigenetic therapy approach to silence covalently closed circular DNA, 03 nov 2022
 - UPDATE -OMICRON (B.1.1.529) SARS-CoV-2 VARIANT, CEE meeting virtual 2019
- Regional Description of Barriers to acces to care in HIV-1 infected women: ELLA study- poster presentation, 20th International AIDS Conference, Melbourne, Australia, July 20–25, 2014
- ELLA study: Barriers to acces to care in HIV-1 infected women -poster at Glasgow 2014
- Participare la a X-a Editie a Zilelor Stiintifice ale Institutului National de Boli Infectioase „Prof. Dr. Matei Bals” cu lucrări poster si prezentări orale. Premiul întâi la sectiunea postere pentru lucrarea: „Osteorenal national screening program for romanian HIV cohort”. 18 credite EMC.
- 23-25 octombrie 2013 – Bucuresti. Participare la a IX-a Editie a Zilelor Stiintifice ale Institutului National de Boli Infectioase „Prof. Dr. Matei Bals” cu lucrări poster si prezentări orale. Premiul întâi la sectiunea postere pentru lucrarea: „Hepatitis B virus vaccination status of sixth year medical students”. 18 credite EMC
- 9 octombrie 2013 – Bucuresti. Participare la “Congresul National de Hepatologie - Editia a XXIII-a” cu lucrare poster: „Hepatitis B in HIV-positive patients – liver fibrosis and antiviral resistance pattern”. Premiul II.
- 30 iunie – 3 iulie 2013 – Kuala Lumpur, Malaezia. Participare la “7th IAS Conference on HIV Pathogenesis, Treatment and Prevention” cu lucrare poster: „MOLBPE12. Evolution of HIV infection in Romanian patients with HBV coinfection since early childhood”, 18 credite EMC

- 21-23 mai 2013 – Paris, Franta. Participare la „30 Years of HIV Science: Imagine the Future” (Bursă de participare din partea Institutului Pasteur din Paris) cu 2 lucrări poster: „Poster #65: HBV serologic status in a cohort of HIV-positive patients from Romania” și „Poster #100: HBV resistance pattern and liver fibrosis in patients coinfecting with HIV and HBV. Case series”
- 17-19 octombrie 2012 – Bucuresti. Prezentări poster la a VIII-a Editie a Zilelor Stiintifice ale Institutului National de Boli Infectioase „Prof. Dr. Matei Bals”: Bolile Infectioase – Sens unic. Abstracte publicate.
 - 17-19 mai 2012 – Sibiu. Participare la al VI-lea Congres National HIV/SIDA.
- 09-12 noiembrie 2011 – Bucuresti. Participare la a VII-a Editie a Zilelor Stiintifice ale Institutului National de Boli Infectioase „Prof. Dr. Matei Bals”
 - “Prospective epidemiological study on the prevalence of HLA B* 5701 in HIV 1 infected patients in the Central Eastern Europe(CEE)”- 6 countries included from CEE: Romania, Bulgaria, Hungaria, Latvia, Lithuania, Slovenia, poster presentation at the National Congress of Infectious Diseases The Days of INBI „Matei Bals”, October 2009
- “Identifying new patterns in lipid and carbohydrate metabolism by modern techniques of diagnosis in HIV infected children and adults with antiretroviral therapy and correlation with cardiovascular risk (Grant SLD-ART)”- Preliminary Results- oral presentation at the HIV Forum Constanta 2009
- “Prospective epidemiological study of the prevalence of HLA B* 5701 in HIV 1 infected patients”- preliminary results, epidemiological study involving 6 countries from CEE including Romania, Bulgaria, Hungaria, Latvia, Lithuania, Slovenia, oral presentation at 5th European HIV Congress held in Vilnius Lithuania May 2009
- Rising Star Project, INBI Matei Bals-Schering, oral presentation “Liver biopsy and noninvasive tests-Fibrotest/Fibroscan- correlation of fibrosis in chronic hepatitis C infected patients”, 23-25 January 2009
- “Q Fever with multiple pulmonary determination”, Adrian Streinu-Cercel, Ruxandra Tanasescu, Anca Streinu-Cercel, Mihai Ionescu, National Congress The Days of INBI „Matei Bals”, „Efficacy versus efficiency in the diagnostic and management of infectious diseases”, Bucharest, October 09-12, 2008
- Titu Maiorescu University Conference for students and young doctors” 28 may 2004 Bucharest, Romania
- “19th International Medical Sciences Student Congress” Istanbul Turkey 6-9 May 2004
- Degree paper: ““Bitherapy Interferon plus Lamivudine in acute Hepatitis B infection.” Prospectiv, open, randomised study, Titu Maiorescu University, Medicine Faculty, september 2005, Bucharest
- “19th International Medical Sciences Student Congress Istanbul Turkey 6-9 May 2004, with the subject “Combine therapy IFN-Lamivudina versus Monotherapy/Lamivudină or IFN in acute VHB hepatites. Efficacy at week 24, 48; safety and adherence’ clinical section,

- Surgery about "Choledocian Chyst" 28 May 2004 at "Titu Maiorescu University Conference for students and young doctors", clinical section
 - Antiviral therapy in acute Hepatitis B", an open, randomized study, which involved 327 patients, treated with Interferon and Lamivudin presented at "19th International Medical Sciences Student Congress" Istanbul Turkey 6-9 May 2004,
 - Anatomy-Immunology, with the study "Acido-bazic modification in adult's Spasmophilia" at "Titu Maiorescu University Conference for students and young doctors", 31 May 2002, preclinical section
 - "Preventing and risk avoiding options in microwave exposure from mobile telephones" at Titu Maiorescu University Conference for students and young doctors" 30 May 2001 Bucharest, Romania,
 - Anatomy, with the study "Maseter muscle vascularisation" at "Titu Maiorescu University Congress for students and young doctors", 2 June 2000, preclinical section,
 - Anatomy, with the study "Microvascularisation of the pterigoidian muscles" at "Titu Maiorescu University Conference for students and young doctors", 2 June 2000, preclinical section,
 - Microbiology with a study about "Prion Diseases" at "Titu Maiorescu University Conference for students and young doctors", 30 May 2001, clinical section
 - 13th Annual International Ain Shams Medical Students' Congress", 13-16 February 2005,: "Ambi-sense (both-way) Hbe seroconversion in chronic hepatitis B under sustained antiviral therapy": open randomized study, Cairo, Egypt 2005
 - Infectious Diseases with "Bitheraphy Interferon plus Lamivudine in acute Hepatitis B infection" at "Titu Maiorescu University Conference for students and young doctors", 28 May 2004,

Activitate stiintifica:

- 2019-prezent PI MYR 204 A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of bulevirtide in Combination with pegylated interferon alfa-2a in Patients with Chronic Hepatitis Delta
- 2018- prezent PI GS US 320 1092 A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects with Chronic Hepatitis B Virus Infection
- 2015-2021 SC/PI M14 423 An open label, multicenter study to evaluate Long Term Outcomes with ABT 450/Ritonavir/ABT 267 (ABT 450/r/ABT 267) and ABT 333 with or without Ribavirin RBV in Adults with Genotype 1 Chronic Hepatitis C virus TOPAZ 1
- 2020-2022 PI for EIG LNF 011 a phase 3 matrix design Lanafarnib/100 mg ritonavir BID with and without 180 mcg PEG IFN alfa 2 a 48 weeks
- 2016- prezent SI/PI VIIV Healthcare protocol 205 888 a multi arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1 (BRIGHT Study)
- 2020-prezent PI ISARIC COVID-19 International Severe Acute Respiratory and Emerging Infections Consortium
- 2020-2021 HS216C17 MRCT PI for a multi center randomised double blind placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Patients with COVID-19-Moderate Type .
- 2021- prezent PI A prospective, randomized, open-label, comparative study to assess the efficacy, safety and tolerability of Aztreonam-Avibactam (ATM-AVI) and best available therapy for the treatment of serious infections due to multi-drug resistant gram-negative bacteria producing metallo-beta-lactamase(MLN)
- 2021-prezent PI A phase 3 prospective, randomized, multicenter, open label, central assessor blinded, parallel group, comparative study to determine the efficacy, safety and tolerability of Aztreonam-Avibactam (ATM-

AVI)±Metronidazole (MTZ)versus Meropenem ±Colistin (MER±COL) for the treatment of serious infections due to gram negative bacteria, including metallo B Lactamase(MBL)- producing multidrug resistant pathogens, for which there are limited or no treatment options.

- 2020-2021 SI/PI AGN 102-3 Un studiu de faza 2b/3 deschis, randomizat care evalueaza siguranta si eficacitatea NP-120 (Ifenprodil) in tratamentul pacientilor spitalizati cu diagnostic confirmat de boala COVID-19
- 2020-2021 PI TSC 100-303 Open-label , pharmacokinetic, pharmacodynamic, ascending dose safety lead-in followed by a single-center, placebo-controlled, double-blind adaptive, safety , pilot study of Trans Sodium Crocetinate (TSC) in SARS-COV2 infected subjects
- 2020-2021 PI AT 03A 001, Un studiu de faza 2, randomizat, dublu-orb, controlat cu placebo , care evalueaza siguranta si eficacitatea AT-527 la subiecti cu COVID -19 in stadiu moderat
- 2022- prezent PI Aphase IIb/III operational seamless, open-label, randomized, sequential, parallel-group adaptive study to evaluate the efficacy and safety of daily intravenous with SOC alone, in patients with acute respiratory distress syndrome (ARDS) triggered by covid-19
- 2022- prezent PI A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR 3434
- 2020 – 2022. Subinvestigator. Regeneron Pharmaceuticals Inc. R10933-10987-COV-2069. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2
- 2020 – 2022. Subinvestigator/PI Regeneron Pharmaceuticals Inc. R10933-10987-COV-2067. A master protocol assessing the safety, tolerability, and efficacy of anti-spike (S) SARS-CoV-2 monoclonal antibodies for the treatment of ambulatory patients with COVID-19
- 2020 – 2022/PI Subinvestigator/PI. Regeneron Pharmaceuticals Inc. R10933-10987-COV-2066. A master protocol assessing the safety, tolerability, and efficacy of anti-spike (S) SARS-CoV-2 monoclonal antibodies for the treatment of hospitalized patients. with COVID-19
- 2020 –2022 PI/Investigator principal. Celltrion Inc. CT-P59 3.2. A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Outpatients with Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection
- 2020 – 2022 PI/. Subinvestigator. Celltrion Inc. CT-P59 1.2. A Pilot Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Virology of CT-P59 in Patient with Mild Symptoms of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection
- 2020 – 2022 Subinvestigator/PI. Diffusion Pharmaceuticals Inc. Protocol 100.303. Open-label, pharmacokinetic, pharmacodynamic, ascending dose safety lead-in followed by a single-center, placebo-controlled, double-blind, adaptive, safety and efficacy, pilot study of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 infected subjects.
- 2020 – 2022 Subinvestigator/PI. Algernon Pharmaceuticals. AGN120-3. A randomized open label phase 2b/3 study of the safety and efficacy of NP-120 (ifenprodil) for the treatment of hospitalized patients with confirmed COVID-19 disease.
- 2020 – 2022 . Subinvestigator/PI. ATEA Pharmaceuticals INC. A randomized open label phase 2b/3 study of the safety and efficacy of AT 03A-001, for the treatment of hospitalized patients with confirmed COVID-19 disease.
- 2019. Investigator principal. F. Hoffmann-La Roche Ltd. FLAGSTONE (CP40617). A phase III, randomized, double-blind placebo-controlled, multicenter study to evaluate the efficacy and safety of baloxavir marboxil in combination with standard of care neuraminidase inhibitor in hospitalized patients with severe influenza.

- decembrie 2018 – 2020 Subinvestigator. Studiu de fază 1. Bayer AG. BAY 80-6946/18041. An open-label non-randomized, phase 1 single dose study to evaluate the pharmacokinetics and safety of copanlisib in subjects with impaired hepatic or renal function in comparison to healthy subjects.
- mai 2018 – ongoing. Subinvestigator. Gilead Sciences. GS-US-320-1092. A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection.
- noiembrie 2017 – iulie 2018. Subinvestigator. Studiu de fază 3. SHIONOGI. CAPSTONE-2. A phase 3, multicenter, randomized, double-blind study of a single dose of S-033188 compared with placebo or oseltamivir 75 mg twice daily in patients with influenza at high risk of influenza complications.
- noiembrie 2017 – septembrie 2018. Subinvestigator. Studiu de fază 2. Cidara Therapeutics, Inc. CD101.IV.2.03. A phase 2, multicenter, randomized, double-blind study of the safety, tolerability, and efficacy of intravenous CD101 vs intravenous caspofungin followed by oral fluconazole step-down in the treatment of subjects with candidemia and/or invasive candidiasis.
- octombrie 2017 – în prezent. Subinvestigator. Studiu de fază 3b. AbbVie M16-135. A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis.
- februarie 2017 – octombrie 2018. Subinvestigator. Studiu de fază 1. Janssen Research and Development. 56136379HPB1001. A Phase 1, double-blind, randomized, placebo-controlled, first-in-human study of orally administered JNJ-56136379 to evaluate safety, tolerability and pharmacokinetics after single ascending doses and one multiple dose regimen in healthy subjects (Part I), and after multiple dose regimens in subjects with chronic hepatitis B (Part II).
- ianuarie 2017 – septembrie 2017. Subinvestigator. Studiu de fază 2. Wockhardt Bio AG W-4873-201. A Phase II, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults.
- ianuarie 2017 – în prezent. Subinvestigator și study coordinator. Studiu de fază 3. Nabriva Therapeutics AG NAB-BC-3781-3102. A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC-3781) Versus Oral Moxifloxacin in Adults with Community-Acquired Bacterial Pneumonia
- mai 2016 – în prezent. Subinvestigator și unblinded study coordinator. Studiu de fază 3. Nabriva Therapeutics AG NAB-BC-3781-3101. A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC-3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults with Community-Acquired Bacterial Pneumonia.
- aprilie 2016 – mai 2018. Subinvestigator. Studiu de fază 1b/2a. Arbutus Biopharma ARB-001467-002. A Phase 1b/2a, Single-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Anti-Viral Activity, and Pharmacokinetics of ARB-001467 In Non-Cirrhotic, HBeAg-Negative and Positive Subjects with Chronic HBV Infection Receiving Nucleos(t)ide Analogue Therapy.
- februarie 2016 – octombrie 2017. Subinvestigator. Studiu farmacoepidemiologic. Gilead Sciences GS-EU-174-1403. Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxicity in Chronic Hepatitis B (CHB)-infected adolescents aged 12 to <18 years in Europe
- februarie 2016 – aprilie 2017. Subinvestigator. Studiu de fază 3. AbbVie M13-590. A randomized, open-label, multicenter study to evaluate the efficacy and safety of ABT-

493/ABT-530 in adults with chronic hepatitis C virus genotype 1 infection (ENDURANCE-1).

- februarie 2016 – decembrie 2017. Subinvestigator. Studiu observațional. Merck, Sharp and Dohme Corp. MK-5172-017. A long-term follow-up study to evaluate the durability of virologic response and/or viral resistance patterns of subjects with chronic hepatitis C who have been previously treated with MK-5172 in a prior clinical trial.
- februarie 2016 – mai 2016. Subinvestigator. Studiu observațional. ImmuneCarta Services. Leukocyte collection by leukapheresis for comprehensive HBV immune-response characterization and establishing references for clinical trials. Assay in a cohort of up to 40 HBV+ subjects.
- octombrie 2015 – noiembrie 2015. Subinvestigator. Phase 1 study. Alios Bipharma Inc. AL-335-601. A randomized, double-blind, placebo-controlled, first-in-human, 3-part study of orally administered AL-335 to evaluate the safety, tolerability and pharmacokinetics of single ascending dosing and food-effect in healthy volunteers, and multiple ascending dosing in subjects with chronic hepatitis C genotype 1 infection.
- mai 2015 – review si evaluare a proiectelor de cercetare submise în competiția de Granturi 2013 organizată de Ministerul Sănătății, Italia
- octombrie 2015 – în prezent. Subinvestigator. Bristol-Myers Squibb. A1438-047-0076. A multi-arm, Phase 3, randomized, placebo controlled, double blind clinical trial to investigate the efficacy and safety of BMS-663068 in heavily treatment experienced subjects infected with multi-drug resistant HIV-1, now HIV, A1438-047_205888 BRIGHT
- iunie 2015 – în prezent. Subinvestigator. Astellas Pharma Europe EXTEND 2819-MA-1002. A phase IIIb/IV randomized, controlled, open-label, parallel group study to compare the efficacy of vancomycin therapy to extended duration fidaxomicin therapy in the sustained clinical cure of *Clostridium difficile* infection in an older population and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)
- martie 2015 – în prezent. Subinvestigator. Gilead Sciences GS-US-330-1401. Safety and efficacy of GS-4774 in combination with tenofovir disoproxil fumarate (TDF) for the treatment of subjects with chronic hepatitis B and who are currently not on treatment.
- martie 2015 – în prezent. Subinvestigator. Merck Sharp & Dohme Corp. MK-5172-077. A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR Prior Treatment Failure Subjects with Chronic HCV GT1, 4 or 6 Infection.
- septembrie 2014 – în prezent. Subinvestigator. Merck Sharp & Dohme Corp. MK-5172-062. An Efficacy and Safety Study of MK-5172 + MK-8742 in the Treatment of Chronic Hepatitis C Virus Genotype 1, 4, 5 or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062) (C-COSTAR)
- iulie 2014 – în prezent. Subinvestigator si Study Coordinator: Gilead Sciences GS-US-320-0108. A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B.
- mai 2015 – în prezent. Subinvestigator. AbbVie M14-423. An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267)
- ianuarie 2014 – în prezent. Subinvestigator si Study Coordinator: Gilead Sciences GS-US-320-0110. A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B.
- noiembrie 2013 – septembrie 2015 Subinvestigator: Activaero Acti-INSP-001. A randomized, double-blind, parallel group, placebo controlled Phase II study to evaluate

the safety and efficacy of two inhaled LASAG regimens and Placebo, applied three times daily in adult hospitalized patients with acute serious influenza.

- iulie 2013 – 2015. Subinvestigator: MALACHITE-II AbbVie M13-862. A Randomized, Open-Labelled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered With Ribavirin Compared to Telaprevir Co-administered With Pegylated Interferon α -2a and Ribavirin in Treatment-Experienced Adults With Chronic Hepatitis C Genotype 1 Virus Infection
- iulie 2013 – 2015 Subinvestigator: MALACHITE I AbbVie M13-774. A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered With and Without Ribavirin Compared to Telaprevir Co-administered With Pegylated Interferon α -2a and Ribavirin in Treatment-Naïve Adults With Chronic Hepatitis C Genotype 1 Virus Infection
- aprilie 2013 – 2014. Subinvestigator: PEARL-III AbbVie M13-961. A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection
- februarie 2013 – în prezent. Subinvestigator: HCVerso 1 Boehringer-Ingelheim 1241.20. Studiu de fază III, randomizat, dublu orb, controlat placebo, pentru BI 207127 în combinație cu faldaprevir și ribavirină în tratamentul pacienților naivi cu infecție cronică cu VHC genotip 1.
- ianuarie 2013 – în prezent. Subinvestigator: GENFIT studiu clinic GFT505-212-7. Studiu pentru evaluarea eficacității și siguranței GFT505 în administrare o dată pe zi în steatohepatită la pacienții cu steatohepatită non-alcoolică (NASH). Studiu multicentric, randomizat, dublu orb, controlat placebo, cu design adaptativ pentru a permite o administrare inițială de GFT505 80 mg versus placebo, urmată de o a doua fază de GFT505 120 mg, după analizarea datelor de siguranță la 6 luni pentru 80 mg la cel puțin 50% din pacienți.
- Sub-investigator for the study Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 24 weeks as combination therapy with pegylated interferon- α 2a and ribavirin (double-blinded,
- (double-blinded, randomized, placebo-controlled, Phase II).
- January 2008 randomised, placebo-controlled, Phase II) Protocol 1220.40- 2009. Participare ca sub-investigator -Protocol 6115A1-3002-WW-vaccin anti pneumococic, in cadrul pacienților infectați HIV- 2010,
- Sub-investigator for the study Phase IIb, multi-centre, randomised, double-blind, active-controlled trial comparing the neuropsychiatric adverse event profile of etravirine 400 mg q.d. versus efavirenz 600 mg q.d. in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in antiretroviral therapy-naïve HIV-1 infected subjects. (SENSE Study) -2009
- Sub-investigator for the study GUARD-C - Global Observational Cohort Study on the Prediction of Unwanted Adverse Effects in Individuals Infected with Chronic Hepatitis C Receiving Peginterferon alfa 2a plus Ribavirin -2009
- Sub-investigator for the study S-Collate (MV 22009) Multicentric, prospective, observational, non-interventional study for the evaluation of treatment response in patients with chronic B hepatitis-2009
- - SLD-ART Nr 3034/2007, winning grant in competition, financed CNMP, project type PC, Program 4- Prioritar field partnership, won in 2008: Pattern identification of lipid and glucidic metabolic through modern diagnostic techniques in child and adult infected HIV patients in therapy with cardiovascular risk correlation- team member for UMF Carol Davila
- „National Adherence program for HIV infected patients under ARV therapy” European HIV Academy- January 2009-January 2010
- Sub-investigator for the study BI 1220.5 “Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon- α 2a and ribavirin

- Sub-investigator for the study MK 0530 a randomised study double blind, multicentric, evaluating the efficacy and safety tolerability MK 0530 regimen plus OBT regimen in HIV infected patients multidrug experienced. Phase III B. August 2008
- Sub-investigator for the study A 4001050 a randomised study double blind, multicentric, evaluating the efficacy and safety tolerability of Maraviroc (CCR5 receptor binding) plus OBT regimen in HIV infected patients multidrug experienced Phase III B. may 2008 -2010
- Sub-investigator for the study BCX812-312 III phase, multicentric, randomised, double blind, placebo-controlled for efficacy and safety of in administration of peramivir at subjects with acute flu without complications, september 2007
- Sub-investigator for the study Nr.1100.1470 Boehringer Ingelheim-Studiu clinic simplu, randomised efficacy and safety virusologic of Atazanavir/Ritonavir plus Tenofovir and Emtricitabina vs Nevirapine in HIV-1 naive (ARTEN)(Faza III b, January 2007
- Sub-investigator for the study ICLA 20-PNE randomised study double blind, multicentric, for efficacy and safety of iv administration of iclaprim versus vancomicina in nosocomial pneumonia, October 2007
- Sub-investigator for the study AI463080 randomised study, for Entecavir for long term therapy with nucleosid/ nucleotid for chronic hepatitis HBV patients. REALM Study.December 2007
- Sub-investigator for the study MSD-801-00 randomised study double blind, multicentric, for efficacy and safety tolerability of different Caspofungin doses for systemic candidoses invasive, March 2006
- Sub-investigator for the study de faza II international multicentric Nuvoicid (oritavancin) single dose or multiple doses for the treatment of complicated skin, June 2007
- Sub-investigator for the study Telbivudine LDT600, Clinical trial protocol CLDT600A2406, A randomized. Open label controlled multi center two year study comparing efficacy and safety of telbivudine 600 mg PO in combination with peginterferon alfa 2° sq 180 nh with peginterferon alfa 2° monotherapy and with telbivudine monotherapy in treatment naive patients with HbeAg positive CHB, phase III B
- Sub-investigator for the study ABF 656 albuferon alfa 2b, Clinical study protocol CABF656A2201. An open label, randomized multicentric active controlled dose ranging study to evaluate the safety and efficacy of albuferon alfa 2b administered every 4 weeks plus ribavirin in interferon alfa naive patients with genotype 1 chronic hepatitis C, phase II b
- Sub-investigator for the international study multicentric phase IV, double blind, evaluating the clinical utility of prospective genetic screening (HLA –B 5701) for the susceptibility to Abacavir in HIV population Abacavir Hypersensitivity CNA 1060 30 , August 2006
- Sub-investigator for the international study multicentric phase IV, double blind, HPR 2001,- for evaluation of safety, PK, and antiviral activity of GW640385/Ritonavir therapy, for HIV-1 infected patients .GSK, July 2005
- Sub-investigator for the international multicentric phase II study, "FBX- GSK" (antifibrosant therapy for chronic hepatitis VHC) - may 2006
- Sub-investigator for the national study "LIPO" (lipodistrofy in HIV infected patients receiving HAART regimens)- April 2006

Sub-investigator for the international multicentric study Evaluating the Therapeutic vaccine therapy efficacy in chronic hepatitis C infected patients non responders to pegylated interferon therapy, June 2006

International projects:

- octombrie 2020 – iunie 2021. Membru în echipa de proiect, investigator principal pentru adulți pentru grantul: "Development of Robust and Innovative Vaccine Effectiveness (DRIVE)", finanțat prin Innovative Medicines Initiative (IMI) 2 Grant Agreement No. 777363.

Partener în proiect: Institutul Național de Boli Infecțioase "Prof. Dr. Matei Balș". Responsabil partener: Dr. Anca Drăgănescu. Rol în proiect: Investigator principal adulți. Coordonator proiect: Fundación Para el Fomento de Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spania. Buget partener: 68 750 EUR.

- octombrie 2020 – iunie 2021. Membru în echipa de cercetare grant "GIHSN prospective epidemiological active surveillance study in Romania". Global Influenza Hospital Surveillance Network (GIHSN) 2018-2019. Finanțare: Foundation for influenza epidemiology, Fondation de France, Sanofi Pasteur. Beneficiar: Institutul Național de Boli Infecțioase "Prof. Dr. Matei Balș". Director de proiect: Dr. Anca Drăgănescu. Buget: 58 000 EUR.

- 2020 – în prezent. Investigator principal. University Medical Center Utrecht. Multi-centre European study of MAJOR Infectious Disease Syndromes (MERMAIDS) – Acute Respiratory Infections (MERMAIDS ARI) 2.0. Funded from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101003589.

- octombrie 2019 – iunie 2020. Membru în echipa de proiect, investigator principal pentru adulți pentru grantul: "Development of Robust and Innovative Vaccine Effectiveness (DRIVE)", finanțat prin Innovative Medicines Initiative (IMI) 2 Grant Agreement No. 777363. Partener în proiect: Institutul Național de Boli Infecțioase "Prof. Dr. Matei Balș". Responsabil partener: Dr. Anca Drăgănescu. Rol în proiect: Investigator principal adulți. Coordonator proiect: Fundación Para el Fomento de Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spania. Buget partener: 80.000 EUR.

- octombrie 2019 – iunie 2020. Membru în echipa de cercetare grant "GIHSN prospective epidemiological active surveillance study in Romania". Global Influenza Hospital Surveillance Network (GIHSN) 2018-2019. Finanțare: Foundation for influenza epidemiology, Fondation de France, Sanofi Pasteur. Beneficiar: Institutul Național de Boli Infecțioase "Prof. Dr. Matei Balș". Director de proiect: Dr. Anca Drăgănescu. Buget: 58 000 EUR.

- **Cornerstone conversation** - A support program designed to help people living with HIV - and the professionals who care for them - hold an expanded dialogue on issues affecting HIV patients, **beyond treatment**, launch in 2015, *Cornerstone Conversations* was **developed in partnership with our Expert Advisory Panel** and will facilitate dialogue around **wider issues** experienced by people living with the condition, with the goal of unlocking broader support to meet more needs: **Wider issues include:** Emotional / Social / Practical / Psychological / Financial / Legal; international expert advisor and local-Romania **project manager, buget 35000 eur**

- MIND EXCHANGE: An educational platform to raise awareness and deliver practical guidance in the management of HIV-associated neurocognitive disorders (HAND), The MIND EXCHANGE programme is an educational initiative driven by an independent steering committee and supported by Abbott International, role clinician expert infectious diseases, romanian representative, 2010

- HIV INFECTED PATIENTS MODELS of CARE, under the aegis of the European HIV/AIDS & Infectious Diseases Academy: Group leader: Prof. Dr. Sorin Rugina – Romania, Anca Streinu-Cercel, Prof. Arjan Harxhi (Albania), Irina Magdalena DUMITRU, Ana Maria SCHWEIZER-Baylor-Black Sea Foundation, BIPAI ROMANIA,

-Management of the HIV Co-infection with HBV and HCV: under the aegis of the European HIV/AIDS & Infectious Diseases Academy: Group leader: Prof. Dr. Tatiana Tcherveniakova, Bulgaria, Toma Tomov – Bulgaria, Prof. dr Carmen Dorobat – Romania, Prof. dr.Lucian Negrutiu – Romania, Dr. Anca Streinu-Cercel – Romania, Prof.dr. A.Cupsa-Romania, Prof.dr. Arvydas Ambrozaitis – Lithuania, Dr. Iosif Marincu-Romania, Arjan Harxhi – Albania

-Scientific coordinator of the project for implementing IL 28 b polymorphism in INBI "Prof.Dr.Matei Bals", in the diagnosis, prognosis and treatment of chronic HCV hepatitis, 2011-2012, in collaboration with UMPC Paris and Pitie-Salpetrie Assistance Publique Paris

- Survey on Central Eastern European (CEE) HIV co-infections: under the aegis of the European HIV/AIDS & Infectious Diseases Academy: Coordinator: ADRIAN STREINU-CERCEL, National Institute for Infectious Diseases "Prof. Dr. Matei Bals", Bucharest(1)Anca Streinu-Cercel (1),Rodica-Alexandra Furnica, Executive Director European HIV/AIDS & Infectious Diseases Academy ,Arvydas Ambrozaitis, Dept. Infectious Diseases, Dermatovenereology and Microbiology, Vilnius University,Lithuania,Carmen Chiriac, Clinic of Infectious Diseases I Târgu Mures, Clinical County Hospital Mures,Felicia Constandis, Hospital of Infectious Diseases Brasov,Augustin Cupsa, University of Medicine and Pharmacy Craiova,Carmen Dorobât, University of Medicine and Pharmacy "Gr.T. Popa" Iasi,Dan Duiculescu, Clinical Hospital of Infectious and Tropical Diseases Dr. Victor Babes", Bucharest,Arjan Harxhi, HIV Ambulatory Clinic, University Hospital Center of Tirana "Mother Theresa" Tirana, Albania,Corina Itu, Clinical Hospital of Infectious Diseases, Cluj-Napoca,Davorka Lukas, HIV/AIDS Outpatient Center, University Hospital for Infectious Diseases, Zagreb, Croatia,Ladislav Machala, AIDS Centre Prague, Czech Republic, Lucian Negrutiu, University of Medicine and Pharmacy Timisoara,Sorin Rugină, "Ovidius" University Constanta,Tatiana Tcherveniakova, Hospital of Infectious Diseases, Sofia, Bulgaria Theresa" Tirana, Albania, Tatiana Tcherveniakova, Hospital of Infectious Diseases, Sofia, Bulgaria, Davorka Lukas, HIV/AIDS Outpatient Center, University Hospital for Infectious Diseases, Zagreb, Croatia,

-Survey of HBV, HCV, HDV viruses with HIV Co-infection, under the aegis of the European HIV/AIDS & Infectious Diseases Academy: Group leader: Adrian Streinu-Cercel, Anca Streinu-Cercel, Arjan Harxhi, HIV Ambulatory Clinic, University Hospital Center of Tirana "Mother

-Drop Test Project- scientific international project for validating rapid HIV tests, compared with ELISA tests; countries included: Romania, Hungary, 2010

Grants, projects obtained through competitions:

Titlul proiectului: Competenta si calitate in serviciile medicale prioritare prin formarea specifica a personalului medical in domeniul bolilor infectioase, Cod SMIS: 108129 Programul Operational Capital Uman, Axa prioritara (AP) 4: Incluziunea sociala si combaterea saraciei, Obiectiv tematic 9: Promovarea incluziunii sociale, combaterea saraciei si a oricarei forme de discriminare (Regulamentul (UE) nr.1304/2013, art.3, alin.1.a) Prioritatea de investitii (PI) 9.iv: Cresterea accesului la servicii accesibile, durabile si de inalta calitate, inclusiv asistenta medicala si servicii sociale de interes general (Regulamentul (UE) nr.1304/2013, art.3, alin.1.a) Obiectivul specific (OS) 4.8: Imbunatatirea nivelului de competente al profesionistilor din sectorul medical. Contract de finantare: nr. POCU/91/4/8/108129 din data de 08.12.2017. – manager proiect 8.12.2017- 12.2018, apoi responsabil formare din 2019

ISR-RO-18-10479 Study Title: National, multicentre retrospective study on HIV patients: HIV specific characteristics and the prevalence of non AIDS related comorbidities in Romania, manager de proiect/investigator principal 06 2019-06 2020 ISR Project RO 19.02 " Prevention and control of the HIV/AIDS and viral hepatitis B and C in Romania" by the Novegian Funds Mechanism 2009-2014 Key Area of Intervention: public health initiative Beneficiary: : National Institute of Infectious Diseases "Prof. Dr. Matei Bals", Bucharest, Romania 2014-2016 member in the management team

Project POS CCE " Infectious Diseases by Biomolecular Romanian Reaserch Center " ID/SMIS:1871/49153 Key Area of Intervention: Beneficiary: : National Institute of Infectious Diseases "Prof. Dr. Matei Bals", Bucharest, Romania 2014-2015- project director "National screening program for CHC HCV" -Give screening a chance in HCV- acronym: GSC HCV,

national program for screening diagnosis, staging chronic hepatitis C in Romania.
Period 8.07.2014-8.07.2017, grant won in private CEE competition J&J funding - manager
de proiect

"Young research projects"- internal competition Carol Davila University 2013, UMF Carol Davila: Nasofaringial microbiota- comparative study involving immunocompetent children enrolled in kindergarten and first class school and immunocompromised children due to HIV infection or hematological disorders" duration 24 months -2013-2015- project director

Project POSDRU/89/1.5/S/64109 „Supporting research through training specialists in the post-PhD study program”. Priority Axis 1. “Education and training in support for growth and development of a knowledge based society“ Key Area of Intervention: 1.5 Doctoral and post-doctoral programs in the support of research. Beneficiary: University of Medicine and Pharmacy “Carol Davila”, Bucharest. Long-term expert. interest for theoretical and applied scientific research in master studies in the field of medical sciences” Priority Axis 1.
“Education and training in support for growth and development of a knowledge based society“ Key Area of Intervention: 1.2. “Quality in higher education” Beneficiary: National Institute of Infectious Diseases “Prof. Dr. Matei Bals”, Bucharest, Romania. 2010-2013 Database coordination expert

P4- Partnerships in Priority Areas (PNCDI2), Domain 4- Health, Evaluating The Molecular Profile Of The Flu Virus Regarding The Resistance To Antivirals And The Respective Clinical Relevance „AVRI”. 2007 – 2010 – member in the research team

P4- Partnerships in Priority Areas (PNCDI2), Domain 4- Health, correlating diagnosis methods regarding the assessment of the involvement of hepatitis viruses in chronic lymphoproliferations – prevalence of infection and identification of certain molecular mechanisms involved in oncogenesis „LIMFO-VIR” 2007 – 2010- member in the research team

P4- Partnerships in Priority Areas (PNCDI2), Domain 6- Biotechnologies, identification of patterns of lipid and glucid metabolism through modern diagnosis techniques in children and adults with HIV infection under antiretroviral treatment and correlation with cardiovascular risk – SLD-ART 2008 – 2011 member in the research team

Project CEEEX 38/2005 – Optimizing the management of HBV-HDV through molecular diagnosis techniques. Study on the epidemiology of HBV-HDV in Bucharest area–2007-2009, member in the research team

Anexe Pentru lista publicatiilor va rugam consultati documentul atasat

Anca Streinu-Cercel